ReviewInternational journal of molecular sciences2022
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 45 citations in OpenAlex.
- Clinical application of liquid biopsy in the diagnosis and treatment of lung cancer: taking ctDNA for example-a narrative review.Journal of thoracic disease · 2026Review
- Adaptive therapy for perioperative non-small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment.Translational oncology · 2026Review
- Liquid biopsy in breast cancer: current biomarker platforms and clinical applications.Exploration of targeted anti-tumor therapy · 2026Review
- Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.Frontiers in oncology · 2026Review
- Circulating tumor DNA in lung cancer: a bibliometric analysis of studies published from 2001 to 2024.Journal of thoracic disease · 2025Article
- Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications.Biomarker research · 2025Review
- LncRNA MIR99AHG serves as a diagnostic marker for early lung cancer and regulates cancer cell growth and metastasis via miR-194-5p.Discover oncology · 2025Article
- Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.Annals of surgery · 2025Article
- Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.Oncotarget · 2025Article
- Treatment of advanced‑stage non‑small cell lung cancer: Current progress and a glimpse into the future (Review).Molecular and clinical oncology · 2025Review
- Current and future therapies for small cell lung carcinoma.Journal of hematology & oncology · 2025Review
- Development and validation of multi-sequence magnetic resonance imaging radiomics models for predicting tumor response to radiotherapy in locally advanced non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).International journal of oncology · 2025Review
- The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer.Discover oncology · 2025Review
- Circulating Tumor DNA and [Diagnostics (Basel, Switzerland) · 2025Article
- The role of circulating tumor DNA in gynecological cancer management.Frontiers in oncology · 2025Review
- Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.Frontiers in oncology · 2025Review
- Functional tumor-derived exosomes in NSCLC progression and clinical implications.Frontiers in pharmacology · 2025Review
- Diagnostics of lung cancer by fragmentated blood circulating cell-free DNA based on machine learning methods.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting treatment paradigms towards increasingly personalized approaches. Liquid biopsies using various circulating analytes provide minimally invasive methods of sampling the molecular content within tumor cells. Plasma-derived circulating tumor DNA (ctDNA), the tumor-derived component of cell-free DNA (cfDNA), is the most extensively studied analyte and has a growing list of applications in the clinical management of NSCLC. As an alternative to tumor genotyping, the assessment of oncogenic driver alterations by ctDNA has become an accepted companion diagnostic via both single-gene polymerase chain reactions (PCR) and next-generation sequencing (NGS) for advanced NSCLC. ctDNA technologies have also shown the ability to detect the emerging mechanisms of acquired resistance that evolve after targeted therapy. Furthermore, the detection of minimal residual disease (MRD) by ctDNA for patients with NSCLC after curative-intent treatment may serve as a prognostic and potentially predictive biomarker for recurrence and response to therapy, respectively. Finally, ctDNA analysis via mutational, methylation, and/or fragmentation multi-omic profiling offers the potential for improving early lung cancer detection. In this review, we discuss the role of ctDNA in each of these capacities, namely, for molecular profiling, treatment response monitoring, MRD detection, and early cancer detection of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.